Cori Gorman, Ph.D., MBA, DNA Bridges, is a Strategist, and Research Scientist with experience in business and drug development aspects of biotechnology industry. She has an outstanding record of achievement in research and drug development in diverse areas including gene therapy, gene expression and transfer, hormone processing, protein transport, and antibody therapeutics and production of recombination of proteins. Cori is also a successful entrepreneur having been a founder of a biotechnology company that completed a successful IPO.
At Genentech, Cori played a key role in the development of a number of marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. She also played a role the early stages of Avastin. Based on her work at Genentech, Cori is also recognized as a pioneer in the development of monoclonal antibody therapeutics and biopharmaceuticals and has co-authored several INDs. An experienced entrepreneur, Cori has worked in all aspects of a start-up company, including raising capital, strategic planning, recruiting scientists, and developing infrastructure.
Our work is centered around a series of Focus Areas that we believe are the future of science and technology.
We’re continually developing new technologies, many of which are available for Commercialization.